{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:07:39Z","timestamp":1789391259922,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Antibody\u2013drug conjugates (ADCs) are entering earlier lines of breast cancer therapy, but evidence guiding treatment after a prior ADC remains limited. We performed a structured narrative synthesis of prospective post\u2013prior-ADC studies, peer-reviewed retrospective cohorts, human translational analyses, functional preclinical studies, regulatory documents, and trial registries through July 23, 2026. No completed trial has randomized clinically comparable patients between alternative ADC sequence orders. DESTINY-Breast02 demonstrates trastuzumab deruxtecan activity after trastuzumab emtansine, whereas DESTINY-Breast03 is a head-to-head construct comparison and not a sequential-treatment study. Retrospective cohorts show that a second ADC can retain activity, but usually report shorter progression-free survival, real-world progression-free survival, or time to treatment failure than with the first ADC. These findings cannot isolate biological cross-resistance from later treatment line, disease evolution, intervening therapy, selection, changing fitness, toxicity, and non-equivalent endpoints. Longitudinal human studies support selected target-level and payload-level mechanisms, including decreased HER2 expression and acquired\n                    <jats:italic>TOP1<\/jats:italic>\n                    alterations; generalized trafficking failure, efflux-mediated cross-resistance, and clinical rescue through linker or payload switching remain predominantly preclinical or hypothesis-generating. Sequential decisions should therefore be anchored to subtype-specific prospective evidence and current indications, then refined by the reason the prior ADC stopped, current target eligibility, central nervous system disease, prior toxicity, organ and marrow reserve, non-ADC alternatives, access, and patient goals. Current evidence supports individualized decision-making, not a validated universal sequence.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1887974","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:54:45Z","timestamp":1789390485000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The \u201cADC-after-ADC\u201d paradigm: navigating cross-resistance and sequencing in breast cancer therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Michael","family":"Asare","sequence":"first","affiliation":[{"name":"Department of Medicine, BronxCare Health System","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinitas Oserefuamen","family":"Okobi","sequence":"additional","affiliation":[{"name":"Department of Medicine, BronxCare Health System","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Karass","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, NewYork-Presbyterian Brooklyn Methodist Hospital","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Tobechukwu","family":"Okobi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, NewYork-Presbyterian Brooklyn Methodist Hospital","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Taiwo","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, NewYork-Presbyterian Brooklyn Methodist Hospital","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody\u2013drug conjugates: Lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"key":"B2","unstructured":"DATROWAY (Datopotamab Deruxtecan-Dlnk) Prescribing Information\n          \n          2026"},{"key":"B3","unstructured":"TRODELVY (Sacituzumab Govitecan-Hziy) Prescribing Information\n          \n          2026"},{"key":"B4","unstructured":"ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Prescribing Information\n          \n          2026"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody\u2013drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: Sacituzumab govitecan and trastuzumab deruxtecan in HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud","year":"2024","journal-title":"Br J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41523-025-00748-5","article-title":"Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)","volume":"11","author":"Huppert","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105330","article-title":"Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer","volume":"10","author":"Tarantino","year":"2025","journal-title":"ESMO Open"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104470","article-title":"The ideal strategies of antibody\u2013drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study","volume":"81","author":"Peng","year":"2025","journal-title":"Breast"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae055","article-title":"Optimal sequential strategies for antibody-drug conjugate in metastatic breast cancer: Evaluating efficacy and cross-resistance","volume":"29","author":"Chen","year":"2024","journal-title":"Oncologist"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf220","article-title":"Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer","volume":"117","author":"Tarantino","year":"2025","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1729-8","article-title":"Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates","volume":"32","author":"Xu","year":"2015","journal-title":"Pharm Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 mutations and cross-resistance to antibody\u2013drug conjugates in patients with metastatic breast cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3321","article-title":"Payload diversification overcomes resistance and guides sequential antibody\u2013drug conjugate therapy in breast cancer","volume":"32","author":"Rampa","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B25","unstructured":"KADCYLA (Ado-Trastuzumab Emtansine) Prescribing Information\n          \n          2026"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013College of American Pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"B27","unstructured":"HER2 Molecular Imaging With 89Zr-Trastuzumab PET\/CT as a Predictive Biomarker for Antibody-Drug Conjugate Sequencing (ZEPHIR-02)"},{"key":"B28","unstructured":"FDA Approves Fam-Trastuzumab Deruxtecan-Nxki With Pertuzumab for Unresectable or Metastatic HER2-Positive Breast Cancer\n          \n          2025"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor\u2013positive human epidermal growth factor receptor 2\u2013negative breast cancer: Primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"B35","unstructured":"Treatment of ADC-Refractory Breast Cancer With Datopotamab Deruxtecan or Trastuzumab Deruxtecan (TRADE-Dxd)"},{"key":"B36","unstructured":"Sequencing Antibody-Drug Conjugates in ER-Positive\/HER2-Low or HER2-Ultralow Metastatic Breast Cancer (SERIES)"},{"key":"B37","unstructured":"Sequencing SG vs. T-Dxd in HER2-Low\/\u200bTROP2-High Metastatic Breast Cancer (STORM)"},{"key":"B38","unstructured":"Alternating Sacituzumab Govitecan and Trastuzumab Deruxtecan in Metastatic or Locally Advanced Triple-Negative Breast Cancer (ALTER)"},{"key":"B39","unstructured":"A Single-Arm Phase II Trial of Sacituzumab Govitecan and Trastuzumab for HER2-Positive Metastatic Breast Cancer After Trastuzumab Deruxtecan (SATEEN)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3\u2013directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3\u2013expressing metastatic breast cancer: a multicenter, phase I\/II trial","volume":"41","author":"Krop","year":"2023","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2\u2010directed antibody\u2010drug conjugate, in patients with HER2\u2010overexpression and HER2\u2010low advanced breast cancer: a phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00242","article-title":"Real-world clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"21","author":"Alaklabi","year":"2025","journal-title":"JCO Oncol Pract"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1887974\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:54:53Z","timestamp":1789390493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1887974\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":42,"alternative-id":["10.3389\/fonc.2026.1887974"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1887974","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1887974"}}